A Phase I, Randomized, Single‑Blind, Placebo‑Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy Subjects.

CNS Drugs
Michael J FosslerMark A Demitrack

Abstract

The delta opioid receptor (DOR) has been identified as a therapeutic target for migraine, with DOR agonists exhibiting low abuse potential compared with conventional µ-opioid agonists. TRV250 is a novel small molecule agonist of the DOR that is preferentially selective for G-protein signaling, with relatively little activation of the β-arrestin2 post-receptor signaling pathway. This selectivity provides reduced susceptibility to proconvulsant activity seen with non-selective DOR agonists. TRV250 significantly reduced nitroglycerin-evoked hyperalgesia in rodents, indicating a potential utility in acute migraine without the risk of seizure activity or abuse potential. This trial evaluated the safety, tolerability, and pharmacokinetics of ascending dose levels of TRV250 administered subcutaneously (SC) and the relative bioavailability of TRV250 administered orally compared with SC administration. This was a two-part, single ascending dose study. Part A included four cohorts of healthy adults (N = 38). Each cohort was dosed on three occasions (placebo and two different dose levels of TRV250, allocated in randomized order and administered by SC route). In Part B, a single cohort of nine subjects received an oral dose of either TRV25...Continue Reading

References

Nov 23, 2006·Pharmacology, Biochemistry, and Behavior·Ingela DanielssonS Stevens Negus
Sep 8, 2010·Handbook of Clinical Neurology·Andrew Charles, K C Brennan
Sep 30, 2010·The Journal of Headache and Pain·Anna FerrariEmilio Sternieri
Dec 3, 2014·Behavioural Brain Research·Paul Chu Sin ChungBrigitte L Kieffer
Dec 22, 2016·Expert Opinion on Investigational Drugs·Viola Spahn, Christoph Stein
Jul 6, 2017·Current Protocols in Neuroscience·Laura S Moye, Amynah A A Pradhan
Dec 13, 2017·Lancet Neurology·Andrew Charles
Dec 14, 2017·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Jonathan Jia Yuan Ong, Milena De Felice
Dec 27, 2017·British Journal of Pharmacology·Isaac J DrippsEmily M Jutkiewicz
Apr 25, 2018·Nature Reviews. Neurology·Lars EdvinssonDiana N Krause
May 4, 2018·British Journal of Pharmacology·Ana Vicente-SanchezAmynah A Pradhan
Dec 17, 2018·Neuropharmacology·Laura S MoyeAmynah A Pradhan
May 19, 2019·The Journal of Headache and Pain·Leda Marina PomesPaolo Martelletti
Jul 11, 2019·Headache·Zachariah Bertels, Amynah Amir Ali Pradhan
Nov 5, 2019·Trends in Cardiovascular Medicine·Dandan ChenGina Price Lundberg

❮ Previous
Next ❯

Methods Mentioned

BETA
pregnancy test

Software Mentioned

ModelRisk
Simulations Plus

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.